Looks like a bear flag in the making on hourly frame
Rexahn Pharma's Archexin has received FDA orphan drug designation for RCC, glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer. Drug data expected early 2015 "Archexin is a potential best-in-class, potent inhibitor of the protein kinase phosphorylated Akt-1, which is over expressed in cancer cells and which we believe plays a critical role in...